secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2026-10-07T13:00:12+00:00
Accession:  0001437749-26-032270
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

BioCardia to present CardiAMP HF II trial design at HFSA; FDA says trial may support approval
--------------------------------------------------------------------------------

- Poster titled "Cardiac Delivery of Autologous Minimally Processed Cell Therapy in HFrEF: Multicenter, Double Blind RCT (CardiAMP HF II)" to be presented at HFSA 2026 in Phoenix, Oct 9-12, 2026.
- Study objective: determine efficacy of high-dose autologous cell treatment for ischemic HFrEF patients on guideline-directed medical therapy but with elevated biomarkers of heart stress.
- FDA approved Category B designation for CardiAMP cell therapy system in three trials; FDA recently agreed ongoing CardiAMP HF II may support approval.
- CEO Peter Altman said the company is advancing the confirmatory CardiAMP HF II trial with world-class centers and has parallel regulatory submissions with FDA and Japan's PMDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774926032270/0001437749-26-032270-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774926032270/bcda20261007_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-032270

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer